Evidence map›Paper›PMID 33512528›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Effectiveness of Contact Precautions to Prevent Transmission of Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci in Intensive Care Units.

Karim Khader, Alun Thomas, W Charles Huskins, Vanessa Stevens, Lindsay T Keegan, Lindsay Visnovsky, Matthew H Samore

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Increasing prevalence of bacteriocin carriage in a six-year hospital cohort ofmedRxiv : the preprint server for health sciences · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Modeling transmission of pathogens in healthcare settings.Current opinion in infectious diseases · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karim KhaderInformatics, Decision-Enhancement, and Analytical Sciences Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Alun ThomasDivision of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
W Charles HuskinsDivision of Pediatric Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Vanessa StevensInformatics, Decision-Enhancement, and Analytical Sciences Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Lindsay T KeeganInformatics, Decision-Enhancement, and Analytical Sciences Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Lindsay VisnovskyInformatics, Decision-Enhancement, and Analytical Sciences Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.
Matthew H SamoreInformatics, Decision-Enhancement, and Analytical Sciences Center of Innovation, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
University of Utah Center for Clinical and Translational Science-UL1UL1TR000105 · NCATS · UNIVERSITY OF UTAH · PI MCCLAIN, DONALD A. · 2012 to 2013
$5.1M
NCATS NIH HHS UL1 TR000105NCATS NIH HHS UL1 TR002538NCEZID CDC HHS U01 CK000585NCEZID CDC HHS U54 CK000456
6 · The paper itself

Abstract

backgroundContact precautions for endemic methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are under increasing scrutiny, in part due to limited clinical trial evidence.

methodsWe retrospectively analyzed data from the Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) trial to model the use of contact precautions in individual intensive care units (ICUs). Data included admission and discharge times and surveillance test results. We used a transmission model to estimate key epidemiological parameters, including the effect of contact precautions on transmission. Finally, we performed multivariate meta-regression to identify ICU-level factors associated with contact precaution effects.

resultsWe found that 21% of admissions (n = 2194) were placed on contact precautions, with most for MRSA and VRE. We found little evidence that contact precautions reduced MRSA transmission. The estimated change in transmission attributed to contact precautions was -16% (95% credible interval, -38% to 15%). VRE transmission was higher than MRSA transmission due to contact precautions, but not significantly. In our meta-regression, we did not identify associations between ICU-level factors and estimated contact precaution effects. Importation and transmission were higher for VRE than for MRSA, but clearance rates were lower for VRE than for MRSA.

conclusionsWe found little evidence that contact precautions implemented during the STAR*ICU trial reduced transmission of MRSA or VRE. We did find important differences in the transmission dynamics between MRSA and VRE. Differences in organism and healthcare setting may impact the efficacy of contact precautions.

Indexed as

Cross InfectionGram-Positive Bacterial InfectionsMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsVancomycin-Resistant EnterococciHumansInfection ControlIntensive Care UnitsRetrospective Studiescontact precautionseffectivenessMRSAtransmissionVRE

Identifiers

PMID33512528
PMCPMC7844588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.